Análise de erros de prescrições de medicamentos Antineoplásicos utilizados no tratamento de Câncer de Mama em um ambulatório de Quimioterapia de Belo Horizonte, Minas Gerais

• Ano de defesa: 2014
• Autor(a) principal: Elaine de Andrade Azevedo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; UFMG
• Palavras-chave em Português: Erros de prescrição; Segurança do paciente; Quimioterapia; Erros de medicação; Antineoplásicos; Segurança de medicamentos; Medicamentos Prescrição; Mamas Câncer; Medicamentos Medidas de segurança; Agentes antineoplásicos
• Link de acesso: http://hdl.handle.net/1843/BUOS-AT3MLB

Introduction: Errors with antineoplastic drugs are considered potentially harmful due to pharmacological and therapeutic characteristics of that drugs. Among them, we highlight the prescription errors, which one can cause serious harm to patients. Studies show wide variation in the frequency of these errors and leave gaps in knowledge about its main determinants. Objective: To analyze the association between types, severity and sociodemographic and clinical care predictors of oncology prescription errors. Metods: Cross-sectional study with assessment of orders issued from September to November 2013 for women with breast cancer treated at a chemotherapy clinic of a Brazilian public hospital. Main outcome assessed were frequency and severity of prescription errors categorized as prescription writing or prescribing decision error.Univariate and multivariate analyzes were performed to identify risk factors. Results: Some 231 antineoplastic drugs were analyzed in 150 orders from 58 patients. Of all orders, 49.3% had prescription writing errors and 80% prescribing decision errors. The error rate for antineoplastic drugs was 52.4% (8.2% for writing, 39.8% for decision and 4.4% for prescription writing and prescribing decision). Of theprescribed drugs, 32% had an infusion time error, 11.3% had an inadequate administration sequence, 5.2% had an error in the daily dose and 4.3% contained dangerous abbreviations. Prescription writing errors were considered of low severity, but some decision errors, such as the infusion of doxorubicin at a higher than recommended rate were considered potentially serious. The chemotherapy, the physician's specialty, the number of medications in the order and the disease staging showed an association with the occurrence of errors.Conclusion: Elevated error rates and high potential for severity for two types of decision errors were observed. The treatment regimen was associated with three types of errors, although in different ways. The physicians oncology specialty, the largest number of antineoplastic drugs in the prescription and the less advanced stage were shown as protective factors against errors. These findings reinforce theneed for a safer antineoplastic drug prescription model.